Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SMART-5: Bazedoxifene/Conjugated Estrogens for Menopause and Osteoporosis
NCT00808132Phase 3Completed
- Sponsor
- Pfizer
- Start
- Jan 2009
- Primary completion
- Feb 2011
- Modality
- Small Molecules
- Countries
- 12
01
Overview
Phase 3, randomised, double-blind trial of bazedoxifene and conjugated estrogens in postmenopausal osteoporosis (5 arms), sponsored by Pfizer. Primary endpoints: Percentage of Participants With Endometrial Hyperplasia at 12 months and Percent Change From Baseline in Bone Mineral Density (BMD) of Lumbar Spine at 12 months. Started Jan 2009; status: completed.
02
Drugs
bazedoxifeneconjugated estrogens
03
Conditions
postmenopausal osteoporosis
Beyond the preview
Go deeper on NCT00808132.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00808132.